Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 12 for:    Merck | Recruiting, Not yet recruiting, Active, not recruiting, Completed Studies | multiple myeloma combination

Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (Myeloma XI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01554852
Recruitment Status : Active, not recruiting
First Posted : March 15, 2012
Last Update Posted : June 11, 2018
Sponsor:
Collaborators:
Celgene
Merck Sharp & Dohme Corp.
Amgen
Information provided by (Responsible Party):
University of Leeds

Brief Summary:

The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib.

Patients who do not have the best response to their initial treatment may then also be given a combination of cyclophosphamide, dexamethasone plus bortezomib.

Patients who are relatively fit may, on their doctor's advice, go on to receive more intensive chemotherapy, supported with a transplant of their own blood cells. This is standard treatment which patients may be offered anyway even if they didn't take part in this study.

After maximal response has been achieved with the treatment described above, and as long as the myeloma has not got worse, patients will be treated with either long-term lenalidomide, lenalidomide with vorinostat, or receive no further treatment, with close observation.


Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance Drug: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) Phase 3

Detailed Description:

The last ten years has seen the introduction of a number of effective new anti-myeloma agents into the clinical arena. These agents have been shown to be highly effective in the relapse setting and now are being introduced as treatment earlier in the disease course.

This study aims to address in the randomised setting some of the key questions concerning the use of thalidomide, bortezomib, lenalidomide, carfilzomib and vorinostat in the initial treatment of multiple myeloma patients.

Newly diagnosed patients of all ages with symptomatic myeloma requiring treatment are eligible.

For initial treatment, thalidomide in combination with cyclophosphamide and dexamethasone, the UK gold standard, will be compared with the newer combination of lenalidomide, cyclophosphamide and dexamethasone with or without carfilzomib.

For patients with a sub-optimal response to initial therapy, the response to the proteasome inhibitor bortezomib will be assessed, as previous studies have demonstrated that it is able to induce responses and improve progression-free and overall survival in patients resistant to standard chemotherapy. Patients young and fit enough to tolerate an autologous transplant will then proceed to high dose melphalan with peripheral blood stem cell rescue and then on to maintenance randomisation. Older or less fit patients will go directly to a maintenance randomisation.

The value of lenalidomide and lenalidomide combined with vorinostat maintenance will then be assessed by randomising eligible patients to receive either lenalidomide, lenalidomide combined with vorinostat maintenance therapy, or close observation.

The primary end points of the study are overall and progression-free survival (OS and PFS). Secondary end points include response and toxicity.

A number of laboratory based studies will also be performed in order to determine patient specific factors predicting overall and progression-free survival and response to treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI)
Study Start Date : May 2010
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022


Arm Intervention/treatment
Active Comparator: Intensive pathway

The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.

Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):

  1. Induction treatment:

    1. CRD regimen - cyclophosphamide, lenalidomide, dexamethasone
    2. CTD regimen - cyclophosphamide, thalidomide, dexamethasone
    3. CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone
  2. Consolidation treatment (depending on response to induction treatment):

    1. VCD regimen - bortezomib, cyclosphosphamide, dexamethasone
    2. No consolidation treatment
  3. High-dose therapy and stem cell transplant
  4. Maintenance treatment:

    1. Lenalidomide maintenance
    2. No maintenance
    3. Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen
Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Other Name: Revlimid (lenalidomide)

Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen
Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days

Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
Days 1 & 8 - cyclophosphamide 500 mg PO Days 1 & 2, 8 & 9, 15 & 16 - carfilzomib 20*/36 mg/m2** IV (*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; **carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 & 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Other Names:
  • Kyprolis (carfilzomib)
  • Revlimid (lenalidomide)

Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen
Days 1, 4, 8 & 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 & 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
Other Name: Velcade (bortezomib)

Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance
Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
Other Name: Revlimid (lenalidomide)

Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance
Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 & 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
Other Names:
  • Revlimid (lenalidomide)
  • Zolinza (vorinostat)

Drug: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
High dose melphalan therapy and autologous stem cell transplant to be given as per local practice

Active Comparator: Non-intensive pathway

The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.

Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:

  1. Induction treatment

    1. CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated
    2. CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated
  2. Consolidation treatment (depending on participant's response to induction treatment):

    1. VCD regimen - bortezomib, cyclosphosphamide, dexamethasone
    2. No consolidation treatment
  3. Maintenance treatment

    1. Lenalidomide maintenance
    2. No maintenance
    3. Lenalidomide plus vorinostat maintenance (*for participants recruited under Protocol v5.0 only*)
Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen
Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
Other Name: Revlimid (lenalidomide)

Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen
Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days

Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen
Days 1, 4, 8 & 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 & 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
Other Name: Velcade (bortezomib)

Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance
Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
Other Name: Revlimid (lenalidomide)

Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance
Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 & 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
Other Names:
  • Revlimid (lenalidomide)
  • Zolinza (vorinostat)




Primary Outcome Measures :
  1. Overall survival [ Time Frame: Time from initial randomisation to the trial death from any cause or last follow-up ]
    Overall survival for induction chemotherapy comparisons is defined as the time from initial randomisation to the trial to death from any cause or last follow-up. Overall survival for maintenance therapy comparisons is defined from the time of maintenance randomisation.

  2. Progression-free survival [ Time Frame: time from initial randomisation to the trial to progression or death from any cause ]
    Progression-free survival for induction chemotherapy comparisons is defined as the time from initial randomisation to the trial to progression or death from any cause. Patients who do not progress will be censored at the last date they were known to be alive and progression-free. Progression-free survival for maintenance therapy comparisons is defined from the time of maintenance randomisation


Secondary Outcome Measures :
  1. Response [ Time Frame: Response will be determined according to the modified international uniform response criteria for multiple myeloma ]
    Disease progression and response rates will be determined according to the modified International uniform response criteria for multiple myeloma

  2. Toxicity [ Time Frame: will be based on adverse events as graded by CTCAE v4.0 ]
    Toxicity will be reported based on adverse events, as graded by CTCAE V4.0 and determined by routine clinical assessments at each centre



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18 years or greater
  • Newly diagnosed as having symptomatic multiple myeloma or non-secretory multiple myeloma
  • Provide written informed consent
  • Women of childbearing potential and male patients whose partner is a woman of child bearing potential must be prepared to use contraception in accordance with (and consent to) the Celgene-approved process for thalidomide and lenalidomide Risk Management and Pregnancy Prevention, or commit to absolute and continuous abstinence
  • Women of child bearing potential must have a negative pregnancy test performed by a healthcare professional in accordance with the Celgene-approved process for thalidomide and lenalidomide Risk Management and Pregnancy Prevention

Exclusion Criteria:

  • Asymptomatic myeloma
  • Solitary plasmacytoma of bone. (Patients with previous solitary plasmacytoma now progressed to symptomatic or non-secretory myeloma are eligible)
  • Extramedullary plasmacytoma (without evidence of myeloma)
  • Previous (<5 years since diagnosis) or concurrent active malignancies, except surgically-removed basal or squamous cell carcinoma of the skin, treated carcinoma in situ of the breast or cervix, or incidental histologic finding of prostate cancer (TMN stage of T1a or 1b). Patients with remote histories (>5 years) of other cured malignancies may be entered.
  • Documented diagnosis of Myelodysplastic Syndrome (MDS) that meets International Prognostic Scoring System (IPSS) criteria for high-risk disease
  • Previous treatment for myeloma, except the following: local radiotherapy to relieve bone pain or spinal cord compression; or prior bisphosphonate treatment; or corticosteroids within the last 3 months
  • Known history of allergy contributable to compounds containing boron or mannitol
  • Grade 2 or greater (NCI criteria) peripheral neuropathy
  • Acute renal failure (unresponsive to up to 72 hours of rehydration, characterised by creatinine >500µmol/L or urine output <400 mL/day or requirement for dialysis)
  • Lactating or breastfeeding
  • Patient has active or prior hepatitis C
  • Caution is advised in patients with a past history of ischaemic heart disease, pericardial disease, acute diffuse infiltrative pulmonary disease or psychiatric disorders, evidence of impaired marrow function or elevated liver function tests, but exclusion is essentially to be at the discretion of the treating clinician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01554852


Locations
Layout table for location information
United Kingdom
112 sites UK wide
United Kingdom, United Kingdom
Sponsors and Collaborators
University of Leeds
Celgene
Merck Sharp & Dohme Corp.
Amgen
Investigators
Layout table for investigator information
Principal Investigator: Graham Jackson Freeman Health System

Additional Information:
The ISRCTN register has further information about the Myeloma XI trial. Click on the link above for further information about the trial  This link exits the ClinicalTrials.gov site Cancer research UK provides helpful information about the intensive arm of the trial. Click here for more information.  This link exits the ClinicalTrials.gov site Cancer research UK provides helpful information about the non-intensive arm of the trial. Click here for more information  This link exits the ClinicalTrials.gov site ASH 2016 abstract: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study  This link exits the ClinicalTrials.gov site ASH 2016 abstract: Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study  This link exits the ClinicalTrials.gov site ASH 2016 abstract: Response adapted induction treatment improves outcomes for myeloma patients; results of the Phase III Myeloma XI study.  This link exits the ClinicalTrials.gov site ASH 2016 abstract: Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI trial.  This link exits the ClinicalTrials.gov site ASCO 2017 abstract: Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study  This link exits the ClinicalTrials.gov site EHA 2017 abstract: QUADRUPLET VS SEQUENTIAL TRIPLET INDUCTION THERAPY FOR MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY. (EHA-3097)  This link exits the ClinicalTrials.gov site EHA 2017 abstract: LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA: PATIENTS: RESULTS OF THE MYELOMA XI STUDY (EHA-1279)  This link exits the ClinicalTrials.gov site NCRI 2017 abstract: The NCRI Myeloma XI study: a large adaptive randomised clinical trial successfully answering a diverse range of key questions in multiple myeloma.  This link exits the ClinicalTrials.gov site ASH 2017 abstract: Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: Results of the Myeloma XI trial  This link exits the ClinicalTrials.gov site ASH 2017 abstract: Minimal residual disease in the maintenance setting in myeloma: prognostic significance and impact of lenalidomide.  This link exits the ClinicalTrials.gov site ASH 2017 abstract: Thrombotic events in patients with myeloma treated with immunomodulatory drugs; results of the Myeloma XI Study  This link exits the ClinicalTrials.gov site ASH 2017 abstract: The mutational landscape of relapse in high risk myeloma is significantly impacted by the depth of response but not maintenance lenalidomide  This link exits the ClinicalTrials.gov site Paper in Blood Cancer Journal: Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial  This link exits the ClinicalTrials.gov site ASH 2016 abstract: Identifying Ultra-High Risk Myeloma by Integrated Molecular Genetic and Gene Expression Profiling  This link exits the ClinicalTrials.gov site ASH 2016 abstract: DNA methylation profiling of myeloma trial patients reveals specific epigenetic changes associated with outcome  This link exits the ClinicalTrials.gov site ASH 2016 abstract: The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)  This link exits the ClinicalTrials.gov site ASH 2016 abstract: Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis  This link exits the ClinicalTrials.gov site IMW 2017 abstract: From plateau to MRD-negative CR: outcomes in the MRC/NCRI series of randomised trials in newly diagnosed patients with multiple myeloma from 1980 to 2016  This link exits the ClinicalTrials.gov site ASH 2017 abstract: The Leeds Risk Profile predicts outcome for older myeloma patients: A prognostic score using frailty biomarkers derived and tested using 2371 clinical trial patients.  This link exits the ClinicalTrials.gov site ASH 2017 abstract: Factors predicting poor outcomes for myeloma patients at different ages: Results from 3894 patients in the Myeloma XI trial.  This link exits the ClinicalTrials.gov site ASH 2017 abstract: Continuous treatment with lenalidomide improves outcomes in newly diagnosed myeloma patients not eligible for autologous stem cell transplant: Results of the Myeloma XI trial  This link exits the ClinicalTrials.gov site ASH 2017 abstract: Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients  This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Leeds
ClinicalTrials.gov Identifier: NCT01554852     History of Changes
Other Study ID Numbers: EudraCT number: 2009-010956-93
First Posted: March 15, 2012    Key Record Dates
Last Update Posted: June 11, 2018
Last Verified: June 2018

Keywords provided by University of Leeds:
myeloma
lenalidomide
Revlimid
cyclophosphamide
dexamethasone
bortezomib
Velcade
vorinostat
Zolinza
stem cell
carfilzomib
Kyprolis

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Dexamethasone acetate
Cyclophosphamide
Lenalidomide
Bortezomib
Melphalan
Thalidomide
Vorinostat
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids